Compare GNW & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNW | IRTC |
|---|---|---|
| Founded | 1871 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 2004 | 2016 |
| Metric | GNW | IRTC |
|---|---|---|
| Price | $10.24 | $111.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $10.50 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 3.2M | 455.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $7,301,000,000.00 | $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | N/A | $15.94 |
| P/E Ratio | $42.15 | ★ N/A |
| Revenue Growth | 0.08 | ★ 26.24 |
| 52 Week Low | $7.84 | $100.85 |
| 52 Week High | $10.69 | $210.01 |
| Indicator | GNW | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 39.20 |
| Support Level | $9.74 | $102.62 |
| Resistance Level | $10.20 | $127.33 |
| Average True Range (ATR) | 0.22 | 4.69 |
| MACD | -0.02 | -1.25 |
| Stochastic Oscillator | 34.66 | 8.43 |
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.